Tag : Keytruda

Latest News

Promega Enters Global Collaboration with Merck to Develop Microsatellite Instability (MSI) Companion Diagnostic for Use with KEYTRUDA®

Newsemia
MADISON, Wis.–(BUSINESS WIRE)–Promega and Merck enter global collaboration to develop Promega’s microsatellite instability (MSI) as a companion diagnostic for use with Keytruda®. Source link...
Latest News

NOXXON PRÄSENTIERT AKTUELLE KLINISCHE DATEN AUS DER NOX-A12 / KEYTRUDA®- PHASE-1/2-KOMBINATIONSSTUDIE AUF DEM ESMO KONGRESS

Newsemia
BERLIN–(BUSINESS WIRE)–NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), ein Biotechnologieunternehmen mit Fokus auf der Verbesserung von Krebstherapien durch eine gezielte Einwirkung auf die Tumormikroumgebung...
Latest News

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage Triple-Negative Breast Cancer (TNBC)

Newsemia
KENILWORTH, N.J.–(BUSINESS WIRE)—- $MRK #ESMO19–KEYTRUDA Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response vs Chemotherapy as Neoadjuvant Therapy in TNBC Source link...
Latest News

New Phase 2 Clinical Trial Results Continue to Demonstrate Potential Clinical Benefit of IMV’s DPX-Survivac in Combination with Merck’s Keytruda in Patients with DLBCL

Newsemia
DARTMOUTH, Nova Scotia–(BUSINESS WIRE)–IMV Inc. (Nasdaq:IMV; TSX:IMV), a clinical stage immuno-oncology corporation, today announced updated data from the ongoing investigator-sponsored SPiReL Phase 2 clinical trial...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy